• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Aspire Acquistion Llc

    4/25/23 1:02:27 PM ET
    $OTEC
    Blank Checks
    Finance
    Get the next $OTEC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Aspire Acquistion LLC

    (Last) (First) (Middle)
    515 MADISON AVE., SUITE 8078

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/13/2023
    3. Issuer Name and Ticker or Trading Symbol
    OceanTech Acquisitions I Corp. [ OTEC ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Class B common stock (1) (1) Class A common stock 2,581,500 (1) D(2)
    Warrants (3) (3) Class A common stock 5,869,880 1 D(2)
    Explanation of Responses:
    1. As described in the issuer's registration statement on Form S-1 (File No. 333-255151) under the heading "Description of Securities-Founder Shares", the Class B common stock, par value $0.0001, will automatically convert into Class A common stock, par value $0.0001, of the issuer at the time of the issuer's initial business combination transaction on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
    2. This Form 3 is being filed by Aspire Acquisition LLC, the sponsor of the issuer (the "Sponsor"). Surendra Ajjarapu, the issuer's director and Chief Executive Officer is the manager of the Sponsor. Mr. Ajjarapu may be deemed to beneficially own shares held by the Sponsor by virtue of his control over the Sponsor. Mr. Ajjarapu disclaims beneficial ownership of the Class B common stock and warrants held by the Sponsor, except to the extent of his respective pecuniary interest.
    3. Each warrant will become exercisable on the later of 12 months from the closing of the Issuer's initial public offering and 30 days the date of completion of the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation.
    /s/ Surendra Ajjarapu, by Nelson Mullins Riley & Scarborough LLP with Power of Attorney 04/21/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OTEC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OTEC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTEC
    SEC Filings

    View All

    SEC Form 425 filed by OceanTech Acquisitions I Corp.

    425 - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    2/13/24 4:52:09 PM ET
    $OTEC
    Blank Checks
    Finance

    OceanTech Acquisitions I Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - OceanTech Acquisitions I Corp. (0001846809) (Filer)

    2/13/24 4:50:55 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form 425 filed by OceanTech Acquisitions I Corp.

    425 - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    1/30/24 4:06:26 PM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OceanTech Acquisitions I Corp. Announces Redemption of Shares

    OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, today announced that on May 30, 2023, at the special meeting of the stockholders of the Company, holders of 1,035,788 shares of Class A common stock of the Company (the "Redeeming Stockholders") exercised the right to redeem such shares. On June 2, 2023, the Company made cash payments to the Redeeming Stockholders totaling $11,233,820 representing approximately $10.84 per share. Following such payments to the Redeeming Stockholders, the Company's trust account had a balance of approximately $8,814,443. About OceanTech Acquisitions I Corp. OceanTech is a blank check company

    6/7/23 9:29:00 AM ET
    $OTEC
    Blank Checks
    Finance

    OceanTech Acquisitions I Corp. Announces Postponement of Special Meeting of Stockholders Until May 30, 2023 at 11:30 a.m. EDT

    OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, previously filed a definitive proxy statement / final prospectus with respect to a special meeting of its stockholders to be held on Friday, May 26, 2023 at 1:00 p.m. EDT (the "Special Meeting") to vote on, among other things, a proposal to approve an amendment to OceanTech's amended and restated certificate of incorporation to extend the date by which OceanTech must consummate its initial business combination from June 2, 2023 by up to twelve (12) one-month extensions through June 2, 2024, or such earlier date as determined by OceanTech's board of directors. The Company is

    5/25/23 11:09:00 PM ET
    $OTEC
    Blank Checks
    Finance

    Regentis Biomaterials Ltd to Become Publicly Listed on Nasdaq via Business Combination with OceanTech Acquisitions I Corp.

    Regentis Biomaterials Ltd ("Regentis") is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health and enhance quality of life of patients. Regentis' lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into a resorbable implant in the knee for the treatment of painful injuries to articular knee cartilage. There is currently no approved off-the-shelf product marketed in the United States for cartilage repair. GelrinC is already approved as a device with a CE mark in Europe, and Regentis is currently conducting a pivotal trial, under the FDA sanctioned protocol, in the United States and Europe. The transac

    5/3/23 7:45:00 AM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Owl Creek Asset Management, L.P.

    4 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)

    6/1/23 9:18:13 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Aspire Acquistion Llc

    3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)

    4/25/23 1:02:27 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Fell Donald G.

    3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)

    4/21/23 6:27:45 PM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by OceanTech Acquisitions I Corp. (Amendment)

    SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    2/13/24 5:54:33 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by OceanTech Acquisitions I Corp. (Amendment)

    SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    2/5/24 2:07:43 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by OceanTech Acquisitions I Corp. (Amendment)

    SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    1/10/24 11:01:25 AM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    Financials

    Live finance-specific insights

    View All

    Regentis Biomaterials Ltd to Become Publicly Listed on Nasdaq via Business Combination with OceanTech Acquisitions I Corp.

    Regentis Biomaterials Ltd ("Regentis") is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health and enhance quality of life of patients. Regentis' lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into a resorbable implant in the knee for the treatment of painful injuries to articular knee cartilage. There is currently no approved off-the-shelf product marketed in the United States for cartilage repair. GelrinC is already approved as a device with a CE mark in Europe, and Regentis is currently conducting a pivotal trial, under the FDA sanctioned protocol, in the United States and Europe. The transac

    5/3/23 7:45:00 AM ET
    $OTEC
    Blank Checks
    Finance